112 related articles for article (PubMed ID: 8337137)
21. [Pathogenesis and treatment of myelodysplastic syndromes and hypoplastic anemia].
Gavrilov OK; Terent'reva OV
Klin Med (Mosk); 1990 Aug; 68(8):23-6. PubMed ID: 2084365
[No Abstract] [Full Text] [Related]
22. The current status of myeloid growth factor therapy.
Galvani DW
J R Coll Physicians Lond; 1991 Jul; 25(3):213-7. PubMed ID: 1717684
[TBL] [Abstract][Full Text] [Related]
23. [Interleukin-3 therapy in patients with aplastic anemia refractory to prior therapies].
Miyairi Y; Murai K; Utsugisawa T; Narigasawa Y; Ito S; Shimosegawa K; Sugawara T; Numaoka H; Ono Y; Ito T; Ishida Y; Kuriya S
Rinsho Ketsueki; 1996 Jan; 37(1):22-8. PubMed ID: 8683863
[TBL] [Abstract][Full Text] [Related]
24. Hematopoietic growth factor therapy of myelodysplastic syndromes.
Arcenas AG; Vadhan-Raj S
Leuk Lymphoma; 1993; 11 Suppl 2():65-9. PubMed ID: 7510197
[No Abstract] [Full Text] [Related]
25. What is the most effective treatment of children with severe aplastic anemia who lack a matched sibling donor?
Johnson FL
Bone Marrow Transplant; 1996 Dec; 18 Suppl 3():S39-44. PubMed ID: 8971407
[TBL] [Abstract][Full Text] [Related]
26. The role of bone marrow transplantation in the treatment of myelodysplastic syndromes.
Schultz AB; Geller RB; Hillyer CD
J Hematother; 1995 Aug; 4(4):323-34. PubMed ID: 7489147
[No Abstract] [Full Text] [Related]
27. Interleukin-3 followed by GM-CSF for delayed engraftment after autologous bone marrow transplantation.
Crump M; Couture F; Kovacs M; Saragosa R; McCrae J; Brandwein J; Huebsch L; Beauregard-Zollinger L; Keating A
Exp Hematol; 1993 Mar; 21(3):405-410. PubMed ID: 8440338
[TBL] [Abstract][Full Text] [Related]
28. Overuse of granulocyte colony-stimulating factor in acute myeloid leukemia, aplastic anemia and myelodysplastic syndrome.
Shinohara K
Intern Med; 2000 Jan; 39(1):82. PubMed ID: 10674858
[No Abstract] [Full Text] [Related]
29. Hematopoietic growth factors in patients receiving intensive chemotherapy for malignant disorders: studies of granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-3 (IL-3) and Flt-3 ligand (Flt3L).
Bruserud O; Foss B; Petersen H
Eur Cytokine Netw; 2001; 12(2):231-8. PubMed ID: 11399510
[TBL] [Abstract][Full Text] [Related]
30. Granulocyte-macrophage colony stimulating factor and interleukin 3: target cells and kinetics of response in vivo.
Aglietta M; Pasquino P; Sanavio F; Stacchini A; Severino A; Fubini L; Morelli S; Volta C; Monteverde A; Piacibello W
Stem Cells; 1993 Jul; 11 Suppl 2():83-7. PubMed ID: 8401260
[TBL] [Abstract][Full Text] [Related]
31. Recombinant human granulocyte-macrophage colony-stimulating factor plus erythropoietin for the treatment of cytopenias in patients with myelodysplastic syndromes.
Stasi R; Pagano A; Terzoli E; Amadori S
Br J Haematol; 1999 Apr; 105(1):141-8. PubMed ID: 10233377
[TBL] [Abstract][Full Text] [Related]
32. Will cytokines alter the treatment of myelodysplastic syndrome?
Schuster MW
Am J Med Sci; 1993 Feb; 305(2):72-8. PubMed ID: 8427296
[TBL] [Abstract][Full Text] [Related]
33. Hematopoietic growth factors in myelodysplastic syndromes.
Blinder VS; Roboz GJ
Curr Hematol Rep; 2003 Nov; 2(6):453-8. PubMed ID: 14561388
[TBL] [Abstract][Full Text] [Related]
34. Interleukin-3 in hematology and oncology: current state of knowledge and future directions.
Mangi MH; Newland AC
Cytokines Cell Mol Ther; 1999 Jun; 5(2):87-95. PubMed ID: 10515681
[TBL] [Abstract][Full Text] [Related]
35. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.
Lemoli RM; Fortuna A; Fogli M; Gherlinzoni F; Rosti G; Catani L; Gozzetti A; Miggiano MC; Tura S
Exp Hematol; 1995 Dec; 23(14):1520-6. PubMed ID: 8542941
[TBL] [Abstract][Full Text] [Related]
36. High-dose cyclophosphamide in the treatment of severe aplastic anemia in children.
Jaime-Pérez JC; González-Llano O; Gómez-Almaguer D
Am J Hematol; 2001 Jan; 66(1):71. PubMed ID: 11426504
[No Abstract] [Full Text] [Related]
37. Cytokine targets in the treatment of myelodysplastic syndromes.
Verma A; List AF
Curr Hematol Rep; 2005 Nov; 4(6):429-35. PubMed ID: 16232378
[TBL] [Abstract][Full Text] [Related]
38. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study.
Balleari E; Rossi E; Clavio M; Congiu A; Gobbi M; Grosso M; Secondo V; Spriano M; Timitilli S; Ghio R
Ann Hematol; 2006 Mar; 85(3):174-80. PubMed ID: 16408206
[TBL] [Abstract][Full Text] [Related]
39. Granulocyte-macrophage colony-stimulating factor in the management of severe ecthyma gangrenosum related to myelodysplastic syndrome.
Bécherel PA; Chosidow O; Berger E; Martin S; Khayat D; Herson S; Francès C
Arch Dermatol; 1995 Aug; 131(8):892-4. PubMed ID: 7632059
[No Abstract] [Full Text] [Related]
40. Recombinant human interleukin-3 and granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for malignant lymphoma.
Fay JW; Bernstein SH
Semin Oncol; 1996 Apr; 23(2 Suppl 4):22-7. PubMed ID: 8600545
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
